Year In Review: New Biologics Total Seven In 2007, But Only Four Will See Market
Executive Summary
FDA approved only one biologic with mass-market potential in 2007, a seasonal flu vaccine. Nearly half of the new biologics approved - three of seven - will not be available commercially. Another three are for orphan indications
You may also be interested in...
Roche’s Mircera Clears FDA, But U.S. Launch Appears Stalled
FDA approved Roche's long-acting erythropoiesis-stimulating agent Mircera for the treatment of anemia associated with chronic renal failure in adults Nov. 14, but a near-term launch of the product appears unlikely given Amgen's legal hold on the market
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.